BostonGene Tumor Portrait™ Tests

The BostonGene Tumor Portrait™ Test, a sophisticated analysis of the tumor and tumor microenvironment (TME), reveals critical drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies.

The BostonGene Tumor Portrait™ test uses DNA whole exome (WES) and RNA transcriptome (RNAseq) sequencing to detect genomic alterations such as single nucleotide variants (SNV), indels, copy number alterations (CNA), tumor mutational burden (TMB), microsatellite instability (MSI), expressed fusions, frameshifts, as well interrogate the expression levels of more than 20,000 genes.

BostonGene integrated genomic and transcriptomic analysis, in concert with the patient’s clinical history, provides information regarding the likely benefits of therapies or therapeutic combinations, suitable NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) treatment recommendations, and ongoing clinical trials.

The BostonGene Tumor Portrait™ Test combines precise data-processing and proprietary algorithms to generate easy-to-understand tumor schematics, the Molecular Functional Portrait™ (Cancer Cell, 2021 Jun 14;39(6):845-865.e7), a personalized tumor map to guide treatment decision-making. Tailoring individualized treatments helps select most effective therapy, avoid unnecessary side effects and decrease treatment costs. The BostonGene Tumor Portrait™ module predicts patient response to immunotherapy and stratifies patients into responders and non-responders.. For patients classified as non-responders to immunotherapy, the BostonGene Tumor Portrait™ Test provides other potential therapy options, utilizing existing guidelines to equip the treating doctor in selecting the ideal therapy route.